Have you or your loved ones been diagnosed with acute lymphoblastic leukemia?

You may be eligible to participate in a acute lymphoblastic leukemia clinical trial.

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia? You may be eligible to participate in a acute lymphoblastic leukemia clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Acute Lymphoblastic Leukemia Clinical Trial in La Jolla CA

NCT01364363 | Interventional

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia?

You may be eligible to participate in a acute lymphoblastic leukemia clinical trial.

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia? You may be eligible to participate in a acute lymphoblastic leukemia clinical trial.

Completed

Male & Female

18 - 69

Years old

This study has recruited 64 Participants

The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Show me more details

Details for the study

Brief Title

Unrelated Donor Stem Cell Transplantation

Official Title

Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors

Brief Summary

The purpose of this study is to provide an opportunity for patients with malignancies or bone <br /> marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic <br /> progenitor cell transplantation using cells from unrelated individuals or cord blood <br /> registries.

Detailed Description

same

Treatments and/or Procedures

Allogeneic transplantation

Allogeneic transplantation with matched unrelated donors

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.

Primary

Bone Marrow and Peripheral Blood Chimerism

Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.

30 days post-transplant

Primary

Bone Marrow and Peripheral Blood Chimerism

Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.

100 days post-transplant

Primary

Bone Marrow and Peripheral Blood Chimerism

Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.

365 days post-transplant

Study Criteria

Inclusion Criteria:

  -  > 18 years of Age

  -  < 70 years

  -  ECOG performance status 0, 1 or 2

  -  Left Ventricular Ejection Fraction > 30%

  -  Creatinine clearance > 40ml/min

  -  Transaminases < 2X normal

  -  Total bilirubin < 2X normal

  -  HIV seronegativity

  -  Weight < 70kg for cord blood transplantation

  -  Ability to cover the cost of the transplant, necessary medications, and
     transportation/housing.

  -  Caregiver must be available while outpatient

Exclusion Criteria:

  -  Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at
     HLA-A, B, C or DR